

Contact

Merck KGaA, Darmstadt, Germany
Investor Relations
Frankfurter Strasse 250
64293 Darmstadt
Germany
Phone: +49 6151 72 3321
e-mail: investor.relations@merckgroup.com
www.merckgroup.com

WKN: 659990
ISIN: DE0006599905
Ticker Symbol: MRK

Financial Statements Q1 2022 – Q1 2023

Content

1 Income statements

- 1.1 Group, quarterly
- 1.2 Life Science, quarterly
- 1.3 Healthcare, quarterly
- 1.4 Electronics, quarterly
- 1.5 Corporate/Others, quarterly
- 1.6 Financial result, quarterly

2 Cash flow statement**3 Balance sheet**

Net sales/Net sales growth by business sector Merck KGaA, Darmstadt, Germany

€ million	2022								2023							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Group	5,197.8	5,568.4	10,766.2	5,805.7	16,571.9	5,660.4	11,466.1	22,232.3	5,293.0							
YoY Δ	567.1	698.2	1,265.3	833.0	2,098.3	447.3	1,280.3	2,545.7	95.2							
Acquisitions Δ	5.0	25.1	30.1	28.8	68.9	16.7	45.5	75.6	9.4							
Fx Δ	203.2	351.8	555.0	448.9	1,003.9	204.5	653.4	1,208.4	43.5							
Organic Δ	358.9	321.2	680.2	355.3	1,035.5	226.2	581.5	1,261.7	42.3							
Life Science	2,445.4	2,647.8	5,093.2	2,680.7	7,773.9	2,606.4	5,287.1	10,380.3	2,488.8							
YoY Δ	314.3	422.3	736.6	431.9	1,168.5	220.1	651.9	1,388.6	41.4							
Acquisitions Δ	5.0	25.1	30.1	28.8	68.9	16.7	45.5	75.6	6.3							
Fx Δ	102.0	164.8	266.6	206.6	473.2	102.7	309.3	575.9	20.9							
Organic Δ	207.4	232.5	439.9	196.5	636.4	100.7	297.2	737.1	14.2							
Healthcare	1,795.0	1,924.2	3,719.1	2,089.3	5,808.5	2,030.3	4,119.6	7,838.7	1,905.5							
YoY Δ	156.0	136.4	292.5	301.7	594.2	155.6	457.4	749.9	110.5							
Acquisitions Δ	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0							
Fx Δ	49.3	110.8	160.1	146.5	306.6	52.7	199.2	359.3	14.8							
Organic Δ	106.8	25.6	132.4	155.3	287.6	102.9	258.2	390.5	95.7							
Electronics	957.4	996.4	1,953.9	1,035.7	2,989.5	1,023.7	2,059.3	4,013.2	900.7							
YoY Δ	96.8	139.5	236.2	99.4	335.6	71.6	171.0	407.2	-56.7							
Acquisitions Δ	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1							
Fx Δ	51.9	76.3	128.3	95.8	224.1	49.1	144.9	273.2	7.7							
Organic Δ	44.8	63.1	107.9	3.6	111.5	22.6	26.1	134.1	-67.6							

	2022								2023							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Group																
YoY %	12.2%	14.3%	13.3%	16.8%	14.5%	8.6%	12.6%	12.9%	1.8%							
Acquisitions %	0.1%	0.5%	0.3%	0.6%	0.4%	0.3%	0.4%	0.4%	0.2%							
Fx %	4.4%	7.2%	5.8%	9.0%	6.9%	3.9%	6.4%	6.1%	0.8%							
Organic %	7.8%	6.6%	7.2%	7.1%	7.2%	4.3%	5.7%	6.4%	0.8%							
Life Science																
YoY %	14.7%	19.0%	16.9%	19.2%	17.7%	9.2%	14.1%	15.4%	1.7%							
Acquisitions %	0.2%	1.1%	0.7%	1.3%	0.9%	0.7%	1.0%	0.8%	0.3%							
Fx %	4.8%	7.4%	6.1%	9.2%	7.2%	4.3%	6.7%	6.4%	0.9%							
Organic %	9.7%	10.4%	10.1%	8.7%	9.6%	4.2%	6.4%	8.2%	0.6%							
Healthcare																
YoY %	9.5%	7.6%	8.5%	16.9%	11.4%	8.3%	12.5%	10.6%	6.2%							
Acquisitions %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%							
Fx %	3.0%	6.2%	4.7%	8.2%	5.9%	2.8%	5.4%	5.1%	0.8%							
Organic %	6.5%	1.4%	3.9%	8.7%	5.5%	5.5%	7.0%	5.5%	5.3%							
Electronics																
YoY %	11.2%	16.3%	13.8%	10.6%	12.6%	7.5%	9.1%	11.3%	-5.9%							
Acquisitions %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%							
Fx %	6.0%	8.9%	7.5%	10.2%	8.4%	5.2%	7.7%	7.6%	0.8%							
Organic %	5.2%	7.4%	6.3%	0.4%	4.2%	2.4%	1.4%	3.7%	-7.1%							

EBITDA pre by business sector Merck KGaA, Darmstadt, Germany

€ million	2022								2023							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Group	1,628.8	1,782.0	3,410.8	1,810.5	5,221.2	1,627.9	3,438.4	6,849.1	1,587.0							
% Margin	31.3%	32.0%	31.7%	31.2%	31.5%	28.6%	30.0%	30.8%	30.0%							
YoY Δ	118.1	205.8	323.9	258.5	582.5	163.7	422.3	746.2	-41.8							
Acquisitions Δ	-3.3	5.3	2.1	7.1	9.2	-27.9	-20.8	-18.7	-6.1							
Fx Δ	96.9	150.0	246.9	135.8	382.7	9.3	145.1	392.0	-7.7							
Organic Δ	24.5	50.5	75.0	115.6	190.6	182.4	298.0	373.0	-27.9							
Life Science	927.1	1,005.7	1,932.8	976.4	2,909.2	850.3	1,826.8	3,759.6	900.6							
% Margin	37.9%	38.0%	37.9%	36.4%	37.4%	32.6%	34.6%	36.2%	36.2%							
YoY Δ	133.5	176.6	310.1	152.8	462.9	10.1	162.9	473.0	-26.5							
Acquisitions Δ	-3.3	5.3	2.1	7.1	9.2	-22.2	-15.1	-13.1	-4.3							
Fx Δ	43.4	51.3	94.8	56.7	151.5	14.3	71.0	165.8	-9.4							
Organic Δ	93.3	119.9	213.2	89.0	302.2	18.1	107.1	320.3	-12.8							
Healthcare	529.1	603.6	1,132.7	710.9	1,843.5	633.1	1,343.9	2,476.6	589.6							
% Margin	29.5%	31.4%	30.5%	34.0%	31.7%	31.2%	32.6%	31.6%	30.8%							
YoY Δ	-3.8	22.6	18.8	170.1	188.8	134.6	304.7	323.5	60.5							
Acquisitions Δ	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0							
Fx Δ	35.6	78.1	113.7	110.4	224.1	27.5	137.9	251.5	4.9							
Organic Δ	-39.4	-55.5	-94.9	59.7	-35.2	107.1	166.8	71.9	55.6							
Electronics	289.3	293.1	582.4	301.6	884.0	308.2	609.8	1,192.2	237.3							
% Margin	30.2%	29.4%	29.8%	29.1%	29.6%	30.1%	29.6%	29.7%	26.4%							
YoY Δ	15.9	35.2	51.1	4.9	56.0	8.4	13.3	64.4	-52.0							
Acquisitions Δ	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.3							
Fx Δ	32.4	40.0	72.4	48.9	121.3	25.8	74.7	147.1	6.6							
Organic Δ	-16.5	-4.8	-21.3	-44.0	-65.3	-17.3	-61.4	-82.7	-57.3							
Corporate/Others	-116.8	-120.3	-237.1	-178.4	-415.5	-163.7	-342.0	-579.2	-140.5							
YoY Δ	-27.5	-28.6	-56.0	-69.1	-125.2	10.5	-58.6	-114.6	-23.7							

	2022								2023							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Group																
YoY %	7.8%	13.1%	10.5%	16.7%	12.6%	11.2%	14.0%	12.2%	-2.6%							
Acquisitions %	-0.2%	0.3%	0.1%	0.5%	0.2%	-1.9%	-0.7%	-0.3%	-0.4%							
Fx %	6.4%	9.5%	8.0%	8.8%	8.3%	0.6%	4.8%	6.4%	-0.5%							
Organic %	1.6%	3.2%	2.4%	7.5%	4.1%	12.5%	9.9%	6.1%	-1.7%							
Life Science																
YoY %	16.8%	21.3%	19.1%	18.6%	18.9%	1.2%	9.8%	14.4%	-2.9%							
Acquisitions %	-0.4%	0.6%	0.1%	0.9%	0.4%	-2.6%	-0.9%	-0.4%	-0.5%							
Fx %	5.5%	6.2%	5.8%	6.9%	6.2%	1.7%	4.3%	5.0%	-1.0%							
Organic %	11.8%	14.5%	13.1%	10.8%	12.4%	2.2%	6.4%	9.7%	-1.4%							
Healthcare																
YoY %	-0.7%	3.9%	1.7%	31.4%	11.4%	27.0%	29.3%	15.0%	11.4%							
Acquisitions %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%							
Fx %	6.7%	13.4%	10.2%	20.4%	13.5%	5.5%	13.3%	11.7%	0.9%							

Income Statement Merck KGaA, Darmstadt, Germany

Group € million	2022								2023								Change YoY											
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY				
Net sales	5,197.8	5,568.4	10,766.2	5,805.7	16,571.9	5,660.4	11,466.1	22,232.3	5,293.0																	1.8%		
Cost of sales	-1,987.0	-2,108.6	-4,095.6	-2,147.5	-6,243.1	-2,284.2	-4,431.6	-8,527.3	-1,972.5																		-0.7%	
thereof amortization of intangible assets	-50.3	-53.2	-103.6	-52.3	-155.9	-51.3	-103.6	-207.1	-48.2																		-4.3%	
Gross profit	3,210.8	3,459.8	6,670.5	3,658.2	10,328.8	3,376.2	7,034.4	13,705.0	3,320.4																		3.4%	
<i>in % of net sales</i>	61.8%	62.1%	62.0%	63.0%	62.3%	59.6%	61.4%	61.6%	62.7%																			
SG&A	-1,451.8	-1,683.1	-3,135.0	-1,782.4	-4,917.3	-1,793.0	-3,575.3	-6,710.3	-1,688.2																		16.3%	
<i>in % of net sales</i>	27.9%	30.2%	29.1%	30.7%	29.7%	31.7%	31.2%	30.2%	31.9%																			
Marketing and selling expenses	-1,087.2	-1,193.6	-2,280.8	-1,223.5	-3,504.3	-1,209.4	-2,432.9	-4,713.7	-1,109.1																		2.0%	
thereof amortization of intangible assets (M&S)	-144.8	-153.7	-298.5	-159.9	-458.4	-158.1	-317.9	-616.4	-151.3																		4.5%	
Administration expenses	-287.2	-330.5	-617.7	-327.9	-945.7	-360.8	-688.7	-1,306.4	-357.9																		24.6%	
Impairment losses and reversals (IFRS 9)	-5.0	-8.7	-13.6	6.2	-7.4	1.9	8.1	-5.5	-2.2																		-56.3%	
Other operating expenses/income	-72.4	-150.4	-222.8	-237.2	-460.0	-224.6	-461.8	-684.6	-219.0																		202.3%	
Impairments**	-2.6	-90.0	-92.6	-10.9	-103.5	-128.4	-139.3	-231.9	-9.7																		271.0%	
Research and development costs	-585.5	-599.6	-1,185.1	-641.7	-1,826.8	-693.7	-1,335.4	-2,520.5	-597.3																		2.0%	
<i>in % of net sales</i>	11.3%	10.8%	11.0%	11.1%	11.0%	12.3%	11.6%	11.3%	11.3%																			
thereof amortization of intangible assets (R&D)	-1.7	-1.7	-3.4	-1.6	-5.0	-1.7	-3.3	-6.7	-4.4																		165.5%	
EBIT	1,173.4	1,177.0	2,350.4	1,234.2	3,584.6	889.6	2,123.7	4,474.2	1,035.0																		-11.8%	
<i>in % of net sales</i>	22.6%	21.1%	21.7%	21.3%	21.6%	15.7%	18.5%	20.1%	19.6%																			
Depreciation and amortization	429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1	455.5																		6.0%	
EBITDA	1,603.0	1,709.4	3,312.3	1,703.9	5,016.2	1,488.1	3,191.9	6,504.3	1,490.5																		-7.0%	
<i>in % of net sales</i>	30.8%	30.7%	30.8%	29.3%	30.3%	26.3%	27.8%	29.3%	28.2%																			
EBITDA pre	1,628.8	1,782.0	3,410.8	1,810.5	5,221.3	1,627.9	3,438.4	6,849.2	1,587.0																		-2.6%	
<i>in % of net sales</i>	31.3%	32.0%	31.7%	31.2%	31.5%	28.8%	30.0%	30.8%	30.0%																			
Financial result	-34.3	-55.1	-89.4	-47.0	-136.4	-50.5	-97.5	-186.9	-22.7																		-33.9%	
Profit before income tax from continuing operations	1,139.1	1,122.0	2,261.0	1,187.2	3,448.2	839.1	2,026.2	4,287.3	1,012.3																		-11.1%	
Income tax	-255.4	-251.7	-507.1	-261.2	-768.3	-179.7	-440.9	-948.0	-212.6																		-16.8%	
<i>Income tax rate</i>	22.4%	22.4%	22.4%	22.0%	22.3%	21.4%	21.8%	22.1%	21.0%																			
Profit after tax from continuing operations	883.7	870.2	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3	799.7																		-9.5%	
Profit after tax from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																		n.m.	
Profit after tax	883.7	870.2	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3	799.7																		-9.5%	
of which: attributable to Merck KGaA shareholders (880.4	867.1	1,747.5	923.2	2,670.7	655.0	1,578.1	3,325.7	796.2																		-9.6%	
of which: attributable to non-controlling interests	3.3	3.1	6.4	2.8	9.2	4.4	7.2	13.6	3.5																		6.3%	
EPS in €	2.02	1.99	4.02	2.12	6.14	1.51	3.63	7.65	1.83																		-9.4%	
thereof from continuing operations	2.02	1.99	4.02	2.12	6.14	1.51	3.63	7.65	1.83																		-9.4%	
thereof from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00																		n.m.	
EPS pre in €*	2.41	2.64	5.05	2.68	7.73	2.32	5.01	10.05	2.36																		-2.1%	
Number of theoretical shares in million	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8																			
Reconciliation to EBITDA pre																												
EBITDA	1,603.0	1,709.4	3,312.3	1,703.9	5,016.2	1,488.1	3,191.9	6,504.3	1,490.5																		-7.0%	
Adjustments																												
thereof: Cost of Sales	1.6	7.8	9.4	6.0	15.4	16.2	22.2	31.6	2.7																		69.6%	
thereof: Marketing and selling expenses	0.5	14.0	14.6	6.4	21.0	11.3	17.7	32.3	-0.9																		n.m.	
thereof: Administration expenses	19.6	29.7	49.3	31.4	80.7	34.4	65.7	115.1	71.7																		264.8%	
thereof: Other operating expenses/income	3.0	14.8	17.7	40.7	58.5	33.0	73.7	91.4	30.9																		>1.000%	
thereof: Research and development	1.1	6.3	7.4	22.1	29.5	45.0	67.1	74.5	-7.9																		n.m.	
Total	25.8	72.6	98.4	106.6	205.0	139.8	246.4	344.9	96.5																		274.1%	
EBITDA pre	1,628.8	1,782.0	3,410.8	1,810.5	5,221.3	1,627.9	3,438.4	6,849.2	1,587.0																		-2.6%	

Due to rounding the sum of individual values may not add up to totals presented.

* For continuing operations.

** Only reflects impairments classified as adjustments.

Reconciliation to EBITDA, EBITDA pre and EPS pre

Group	2022								2023								Change YoY								
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	
€ million																									
a) Reconciliation to EBITDA and EBITDA pre																									
EBITDA																									
EBIT	1,173.4	1,177.0	2,350.4	1,234.2	3,584.6	889.6	2,123.7	4,474.2	1,035.0																-11.8%
Depreciation and amortization	429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1	455.5																6.0%
Regular depreciation and amortization*	230.2	233.7	463.9	245.0	708.9	258.9	503.9	967.8	242.0																5.1%
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0																n.m.
Amortization of purchased intangible assets	196.8	208.7	405.4	213.8	619.2	211.0	424.8	830.2	203.8																3.6%
Impairments (net)**	2.6	90.0	92.6	10.9	103.5	128.4	139.3	231.9	9.7																271.0%
Total	1,603.0	1,709.4	3,312.3	1,703.9	5,016.2	1,488.1	3,191.9	6,504.3	1,490.5																-7.0%
Adjustments																									
Acquisition costs	1.5	8.6	10.1	7.3	17.4	11.6	18.8	28.9	9.2																494.7%
Restructuring costs	8.3	37.8	46.1	63.1	109.2	89.2	152.3	198.4	44.3																431.4%
Integration costs/IT costs	20.0	24.2	44.1	22.7	66.9	20.7	43.4	87.5	23.5																17.7%
Gain (-)/ losses (+) on the divestment of businesses	-10.3	-21.6	-31.9	-4.1	-36.0	-1.5	-5.6	-37.5	0.3																n.m.
Other one-time costs	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2																208.4%
Total	25.8	72.6	98.4	106.6	205.0	139.8	246.4	344.9	96.5																274.1%
EBITDA pre	1,628.8	1,782.0	3,410.8	1,810.5	5,221.3	1,627.9	3,438.4	6,849.2	1,587.0																-2.6%
b) Reconciliation to EPS pre																									
1) Reconciliation starting from EBITDA pre																									
EBITDA pre	1,628.8	1,782.0	3,410.8	1,810.5	5,221.3	1,627.9	3,438.4	6,849.2	1,587.0																-2.6%
Regular depreciation and amortization*	-230.2	-233.7	-463.9	-245.0	-708.9	-258.9	-503.9	-967.8	-242.0																5.1%
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	-0.2	-0.2	-0.2	0.0																n.m.
Financial result	-34.3	-55.1	-89.4	-47.0	-136.4	-50.5	-97.5	-186.9	-22.7																-33.9%
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																
Profit before income tax pre	1,364.3	1,493.2	2,857.5	1,518.5	4,375.9	1,318.3	2,836.7	5,694.2	1,322.3																-3.1%
Income tax pre	-313.8	-343.4	-657.2	-349.2	-1,006.5	-303.2	-652.5	-1,309.7	-290.9																-7.3%
underlying tax rate	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	22.0%																
Non-controlling interest	-3.3	-3.1	-6.4	-2.8	-9.2	-4.4	-7.2	-13.6	-3.5																6.3%
Net income pre	1,047.2	1,146.7	2,193.8	1,166.4	3,360.3	1,010.7	2,177.1	4,371.0	1,027.9																-1.8%
EPS pre in €***	2.41	2.64	5.05	2.68	7.73	2.32	5.01	10.05	2.36																-2.1%
2) Reconciliation starting from Profit before tax																									
Profit before income tax	1,139.1	1,122.0	2,261.0	1,187.2	3,448.2	839.1	2,026.2	4,287.3	1,012.3																-11.1%
Amortization of purchased intangible assets	196.8	208.7	405.4	213.8	619.2	211.0	424.8	830.2	203.8																3.6%
Impairments**	2.6	90.0	92.6	10.9	103.5	128.4	139.3	231.9	9.7																271.0%
Adjustments																									
Acquisition costs	1.5	8.6	10.1	7.3	17.4	11.6	18.8	28.9	9.2																494.7%
Restructuring costs	8.3	37.8	46.1	63.1	109.2	89.2	152.3	198.4	44.3																431.4%
Integration costs/IT costs	20.0	24.2	44.1	22.7	66.9	20.7	43.4	87.5	23.5																17.7%
Gain (-)/ losses (+) on the divestment of businesses	-10.3	-21.6	-31.9	-4.1	-36.0	-1.5	-5.6	-37.5	0.3																n.m.
Other one-time costs	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2																208.4%
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																
Total adjustments	25.8	72.6	98.4	106.6	205.0	139.8	246.4	344.9	96.5																274.1%
Profit before income tax pre	1,364.3	1,493.2	2,857.5	1,518.5	4,375.9	1,318.3	2,836.7	5,694.2	1,322.3																-3.1%
Income tax pre	-313.8	-343.4	-657.2	-349.2	-1,006.5	-303.2	-652.5	-1,309.7	-290.9																-7.3%
underlying tax rate	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	23.0%	22.0%																
Total costs excluded from Net income	166.8	279.5	446.3	243.2	689.5	355.7	599.0	1,045.3	231.7																38.9%
Total costs excluded from EPS in €	0.38	0.64	1.03	0.56	1.59	0.82	1.38	2.40	0.53																39.5%
Non-controlling interest	-3.3	-3.1	-6.4	-2.8	-9.2	-4.4	-7.2	-13.6	-3.5																6.3%
Net income pre	1,047.2	1,146.7	2,193.8	1,166.4	3,360.2	1,010.7	2,177.1	4,371.0	1,027.9																-1.8%
EPS pre in €***	2.41	2.64	5.05	2.68	7.73	2.32	5.01	10.05	2.36																-2.1%
Number of theoretical shares in million	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8																

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** Only reflects impairments classified as adjustments.

*** For continuing operations.

Breakdown of depreciation and amortization and adjustments

Group € million	Division	2022									2023									Change YoY						
		Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	
a) Depreciation and amortization																										
Regular depreciation and amortization*		all	230.2	233.7	463.9	245.0	708.9	258.9	503.9	967.8	242.0															5.1%
Impairments not adjusted		all	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0															n.m.
Amortization of purchased intangible assets																										
	Life Science	LS	109.9	121.1	231.0	123.5	354.4	123.5	246.9	477.9	118.2															7.5%
	Healthcare	HC	1.4	1.3	2.8	1.3	4.0	0.3	1.5	4.3	1.5															8.5%
	Electronics	EL	85.4	86.3	171.7	89.0	260.7	87.3	176.3	348.0	84.1															-1.6%
	Total		196.8	208.7	405.4	213.8	619.2	211.0	424.8	830.2	203.8														3.6%	
Impairments (net)**		all	2.6	90.0	92.6	10.9	103.5	128.4	139.3	231.9	9.7															271.0%
Total depreciation and amortization			429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1	455.5															6.0%
b) Adjustments																										
Acquisition costs			1.5	8.6	10.1	7.3	17.4	11.6	18.8	28.9	9.2															494.7%
Restructuring costs																										
	Life Science	LS	-3.1	13.1	10.0	28.3	38.2	2.3	30.6	40.6	0.4															n.m.
	Healthcare	HC	1.9	8.3	10.2	24.5	34.7	56.3	80.7	91.0	-7.3															n.m.
	Electronics	EL	4.7	8.5	13.1	3.4	16.6	14.0	17.4	30.6	2.2															-53.7%
	Corporate and Other	CO	4.8	7.9	12.8	7.0	19.8	16.5	23.5	36.3	49.0															>1.000%
	Total		8.3	37.8	46.1	63.1	109.2	89.2	152.3	198.4	44.3															431.4%
Integration costs/IT costs																										
	Integration Cost	LS/EL/CO	5.0	2.2	7.1	-2.1	5.0	4.2	2.1	9.2	1.9															-61.2%
	ERP/HR systems	all	15.0	22.0	37.0	24.8	61.9	16.4	41.3	78.3	21.6															43.7%
	Total		20.0	24.2	44.1	22.7	66.9	20.7	43.4	87.5	23.5															17.7%
Gain (-)/ losses (+) on the divestment of businesses																										
	Costs related to former business activities	CO	-10.3	-11.5	-21.8	-4.1	-25.9	3.2	-0.9	-22.7	0.0															-100.0%
	Costs related to former business activities	EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0															n.m.
	Sale of CH, Allergopharma and others	HC	0.0	-10.1	-10.1	0.0	-10.1	-4.7	-4.7	-14.8	0.3															n.m.
	Costs related to former business activities	LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0															n.m.
	Total		-10.3	-21.6	-31.9	-4.1	-36.0	-1.5	-5.6	-37.5	0.3														n.m.	
Other one-time costs																										
	Others	HC	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0															-100.0%
		LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0															n.m.
		EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0															n.m.
		CO	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2															
	Total		6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2															208.4%
Total adjustments			25.8	72.6	98.4	106.6	205.0	139.8	246.4	344.9	96.5															274.1%

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Life Science

€ million

	2022								2023								Change YoY												
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY					
Net sales	2,445.4	2,647.8	5,093.2	2,680.7	7,773.9	2,606.4	5,287.1	10,380.3	2,486.8																1.7%				
Cost of sales	-965.1	-1,052.3	-2,017.4	-1,070.5	-3,087.9	-1,192.1	-2,262.6	-4,280.0	-999.2																	3.5%			
thereof amortization of intangible assets	-13.5	-16.7	-30.2	-15.2	-45.4	-15.1	-30.2	-60.4	-13.3																	-1.0%			
Gross profit	1,480.4	1,595.5	3,075.8	1,610.2	4,686.0	1,414.4	3,024.5	6,100.4	1,487.5																	0.5%			
<i>in % of net sales</i>	60.5%	60.3%	60.4%	60.1%	60.3%	54.3%	57.2%	58.8%	59.8%																				
SG&A	-669.0	-731.6	-1,400.5	-785.3	-2,185.8	-707.4	-1,492.6	-2,893.2	-711.3																	6.3%			
<i>in % of net sales</i>	27.4%	27.6%	27.5%	29.3%	28.1%	27.1%	28.2%	27.9%	28.6%																				
Marketing and selling expenses	-552.0	-608.8	-1,160.8	-633.9	-1,794.7	-605.4	-1,239.2	-2,400.1	-567.5																		2.8%		
thereof amortization of intangible assets (M&S)	-95.6	-103.6	-199.2	-107.5	-306.7	-107.7	-215.2	-414.4	-101.4																		6.1%		
Administration expenses	-91.5	-102.8	-194.2	-112.0	-306.2	-93.4	-205.4	-399.7	-105.0																		14.8%		
Impairment losses and reversals (IFRS 9)	-1.7	-7.6	-9.3	1.7	-7.7	-0.9	0.8	-8.5	-1.1																		-37.1%		
Other operating expenses/income	-23.8	-12.3	-36.1	-41.1	-77.2	-7.7	-48.8	-84.9	-37.8																		58.4%		
Impairments**	-1.3	0.0	-1.3	0.0	-1.3	-23.2	-23.2	-24.5	0.0																		-100.0%		
Research and development costs	-88.1	-98.5	-186.7	-105.7	-292.3	-106.8	-212.5	-399.2	-103.8																		17.8%		
<i>in % of net sales</i>	3.6%	3.7%	3.7%	3.9%	3.8%	4.1%	4.0%	3.8%	4.2%																				
thereof amortization of intangible assets (R&D)	-0.8	-0.8	-1.6	-0.8	-2.4	-0.7	-1.5	-3.1	-3.4																		327.5%		
EBIT	723.3	765.4	1,488.6	719.2	2,207.9	600.2	1,319.4	2,808.0	672.4																		-7.0%		
<i>in % of net sales</i>	29.6%	28.9%	29.2%	26.8%	28.4%	23.0%	25.0%	27.1%	27.0%																				
Depreciation and amortization	198.3	209.9	408.2	216.6	624.9	244.9	461.5	869.7	211.7																		6.7%		
EBITDA	921.6	975.3	1,896.9	935.9	2,832.7	845.0	1,780.9	3,677.8	884.0																			-4.1%	
<i>in % of net sales</i>	37.7%	36.8%	37.2%	34.9%	36.4%	32.4%	33.7%	35.4%	35.5%																				
EBITDA pre	927.1	1,005.7	1,932.8	976.4	2,909.2	850.3	1,826.8	3,759.6	900.6																			-2.9%	
<i>in % of net sales</i>	37.9%	38.0%	37.9%	36.4%	37.4%	32.6%	34.6%	36.2%	36.2%																				
Reconciliation to EBITDA pre																													
EBITDA	921.6	975.3	1,896.9	935.9	2,832.7	845.0	1,780.9	3,677.8	884.0																			-4.1%	
Adjustments																													
thereof: Cost of Sales	0.1	3.0	3.1	2.4	5.5	1.2	3.7	6.7	0.2																			199.6%	
thereof: Marketing and selling expenses	0.1	11.3	11.4	4.8	16.2	0.3	5.1	16.4	-1.2																			n.m.	
thereof: Administration expenses	7.2	9.0	16.3	10.2	26.4	-4.3	5.9	22.2	11.1																			52.8%	
thereof: Other operating expenses/income	-1.9	7.0	5.0	23.1	28.2	8.4	31.5	36.5	6.4																			n.m.	
thereof: Research and development	0.1	0.1	0.2	0.0	0.2	-0.3	-0.3	-0.1	0.0																			-89.3%	
Total	5.5	30.4	35.9	40.5	76.5	5.3	45.8	81.8	16.5																			199.6%	
EBITDA pre	927.1	1,005.7	1,932.8	976.4	2,909.2	850.3	1,826.8	3,759.6	900.6																				-2.9%

Due to rounding the sum of individual values may not add up to totals presented.

Income Statement Merck KGaA, Darmstadt, Germany

Healthcare

€ million

	2022								2023								Change YoY									
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY		
Net sales	1,795.0	1,924.2	3,719.1	2,089.3	5,808.5	2,030.3	4,119.6	7,838.7	1,905.5																6.2%	
Cost of sales	-460.7	-483.5	-944.3	-481.3	-1,425.5	-499.4	-980.7	-1,925.0	-446.6																	-3.1%
thereof amortization of intangible assets	-1.2	-1.2	-2.4	-1.2	-3.5	-1.3	-2.5	-4.9	-1.2																	-0.9%
Gross profit	1,334.2	1,440.7	2,774.9	1,608.1	4,382.9	1,530.8	3,138.9	5,913.8	1,458.9																	9.3%
<i>in % of net sales</i>	74.3%	74.9%	74.6%	77.0%	75.5%	75.4%	76.2%	75.4%	76.6%																	
SG&A	-482.9	-601.3	-1,084.2	-570.7	-1,654.9	-670.0	-1,240.7	-2,324.9	-543.9																	12.6%
<i>in % of net sales</i>	26.9%	31.2%	29.2%	27.3%	28.5%	33.0%	30.1%	29.7%	28.5%																	
Marketing and selling expenses	-375.6	-416.9	-792.5	-412.9	-1,205.4	-438.9	-851.8	-1,644.3	-380.6																	1.3%
thereof amortization of intangible assets (M&S)	-0.2	-0.2	-0.4	-0.1	-0.5	1.1	1.0	0.6	-0.3																	29.8%
Administration expenses	-71.2	-81.1	-152.3	-83.5	-235.8	-77.5	-161.0	-313.3	-75.5																	6.0%
Impairment losses and reversals (IFRS 9)	-3.7	-0.5	-4.2	4.5	0.3	2.2	6.7	2.5	-1.0																	-73.5%
Other operating expenses/income	-32.4	-102.9	-135.3	-78.7	-214.0	-155.8	-234.6	-369.8	-86.8																	167.7%
Impairments**	-0.8	-89.9	-90.8	-0.5	-91.2	-95.7	-96.2	-187.0	0.6																	n.m.
Research and development costs	-397.4	-400.7	-798.1	-431.4	-1,229.5	-464.8	-896.2	-1,694.3	-395.3																	-0.5%
<i>in % of net sales</i>	22.1%	20.8%	21.5%	20.6%	21.2%	22.9%	21.8%	21.6%	20.7%																	
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1																	n.m.
EBIT	453.9	438.7	892.6	606.0	1,498.5	396.1	1,002.0	1,894.6	519.7																	14.5%
<i>in % of net sales</i>	25.3%	22.8%	24.0%	29.0%	25.8%	19.5%	24.3%	24.2%	27.3%																	
Depreciation and amortization	71.7	164.0	235.7	76.7	312.4	177.9	254.6	490.2	72.9																	1.7%
EBITDA	525.6	602.7	1,128.3	682.6	1,810.9	573.9	1,256.6	2,384.8	592.6																	12.8%
<i>in % of net sales</i>	29.3%	31.3%	30.3%	32.7%	31.2%	28.3%	30.5%	30.4%	31.1%																	
EBITDA pre	529.1	603.6	1,132.7	710.9	1,843.5	633.1	1,343.9	2,476.6	589.6																	11.4%
<i>in % of net sales</i>	29.5%	31.4%	30.5%	34.0%	31.7%	31.2%	32.6%	31.6%	30.9%																	
Reconciliation to EBITDA pre																										
EBITDA	525.6	602.7	1,128.3	682.6	1,810.9	573.9	1,256.6	2,384.8	592.6																	12.8%
Adjustments																										
thereof: Cost of Sales	0.4	1.1	1.5	0.8	2.3	1.3	2.0	3.6	0.2																	-52.0%
thereof: Marketing and selling expenses	0.4	1.4	1.8	1.2	3.1	9.8	11.0	12.9	0.3																	-24.4%
thereof: Administration expenses	2.0	2.9	4.9	4.1	9.0	8.5	12.6	17.5	4.0																	103.6%
thereof: Other operating expenses/income	0.0	-10.1	-10.1	0.0	-10.1	-4.8	-4.8	-14.8	0.3																	n.m.
thereof: Research and development	0.7	5.5	6.3	22.1	28.4	44.3	66.4	72.7	-7.8																	n.m.
Total	3.5	0.9	4.4	28.2	32.6	59.1	87.3	91.8	-3.0																	n.m.
EBITDA pre	529.1	603.6	1,132.7	710.9	1,843.5	633.1	1,343.9	2,476.6	589.6																	11.4%

Due to rounding the sum of individual values may not add up to totals presented.

Income Statement Merck KGaA, Darmstadt, Germany
Corporate and Other

€ million

	2022								2023								Change YoY									
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY		
Net sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																n.m.	
Cost of sales	-1.2	-2.0	-3.2	-4.7	-7.9	-0.8	-5.5	-8.7	-0.9																-24.8%	
thereof amortization of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																n.m.	
Gross profit	-1.2	-2.0	-3.2	-4.7	-7.9	-0.8	-5.5	-8.7	-0.9																-24.8%	
SG&A	-123.0	-146.0	-269.0	-204.0	-473.1	-200.4	-404.5	-673.5	-217.8																77.0%	
Marketing and selling expenses	-4.0	-4.7	-8.7	-4.1	-12.8	5.9	1.8	-7.0	-2.8																-28.5%	
thereof amortization of intangible assets (M&S)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																4.6%	
Administration expenses	-96.3	-113.8	-210.1	-99.3	-309.3	-156.3	-255.6	-465.6	-144.4																50.0%	
Impairment losses and reversals (IFRS 9)	0.2	-0.3	-0.1	0.3	0.2	0.7	1.0	0.9	0.0																-87.2%	
Other operating expenses/income	-23.0	-27.2	-50.2	-100.9	-151.1	-50.7	-151.6	-201.8	-70.6																207.0%	
Impairments**	-0.3	0.0	-0.3	0.0	-0.3	-0.1	-0.1	-0.4	0.0																-100.0%	
Research and development costs	-24.7	-27.5	-52.2	-26.2	-78.4	-40.4	-66.6	-118.8	-24.1																-2.5%	
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																n.m.	
EBIT	-148.9	-175.5	-324.4	-234.9	-559.3	-241.6	-476.5	-800.9	-242.8																63.0%	
Depreciation and amortization	25.9	24.9	50.8	26.2	77.0	28.0	54.2	105.1	28.4																9.5%	
EBITDA	-123.0	-150.6	-273.6	-208.7	-482.3	-213.6	-422.3	-695.9	-214.4																74.3%	
EBITDA pre	-116.8	-120.3	-237.1	-178.4	-415.5	-163.7	-342.0	-579.2	-140.5																20.3%	
Reconciliation to EBITDA pre																										
EBITDA	-123.0	-150.6	-273.6	-208.7	-482.3	-213.6	-422.3	-695.9	-214.4																	74.3%
Adjustments																										
thereof: Cost of Sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2																>1.000%	
thereof: Marketing and selling expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																-100.0%	
thereof: Administration expenses	10.2	15.8	26.0	15.9	41.9	25.2	41.1	67.1	54.6																438.1%	
thereof: Other operating expenses/income	-3.9	14.4	10.4	14.5	24.9	24.7	39.2	49.6	19.0																n.m.	
thereof: Research and development	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																n.m.	
Total	6.2	30.2	36.4	30.3	66.8	49.9	80.2	116.7	73.9																>1.000%	
EBITDA pre	-116.8	-120.3	-237.1	-178.4	-415.5	-163.7	-342.0	-579.2	-140.5																20.3%	

Due to rounding the sum of individual values may not add up to totals presented.

Cash Flow Statement Merck KGaA, Darmstadt, Germany
Group

€ million

Profit after tax

	2022								2023								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Profit after tax	883.7	870.2	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3	799.7								-9.5%							
Depreciation/amortization/impairment losses/reversals of impairment losses of tangible assets	429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1	455.5								6.0%							
of intangible assets	206.7	208.8	415.4	219.3	634.7	252.7	472.0	887.4	216.6								4.8%							
Changes in working capital	222.9	323.6	546.5	250.4	796.8	345.8	596.2	1,142.7	238.9								7.2%							
Changes in inventories	-322.3	-324.9	-647.2	-180.7	-827.9	-68.8	-269.5	-916.7	-233.9								-30.3%							
Changes in trade accounts receivable	-186.4	-200.7	-387.1	-248.6	-835.7	31.5	-217.2	-604.2	-322.5								73.0%							
Changes in trade accounts payable/ refund liabilities	-343.1	-193.8	-536.9	149.1	-387.8	-25.3	123.8	-413.1	-116.5								-66.0%							
Changes in provisions ¹	207.2	69.6	276.8	-81.2	195.6	-95.0	-176.1	100.7	215.1								3.8%							
Changes in other assets and liabilities ¹	106.6	-92.5	14.1	111.2	125.3	153.7	264.9	279.0	-8.0								n.m.							
Neutralization of gain/loss on disposal of fixed assets and other disposals	-233.6	-132.9	-366.6	234.5	-132.1	-313.2	-78.7	-445.3	-187.0								-20.0%							
Other non-cash income and expenses	-26.8	-12.1	-38.9	-3.7	-42.5	-5.8	-9.4	-48.3	-0.2								-99.3%							
Operating Cash Flow	2.9	12.2	15.1	-5.3	9.8	11.2	5.9	21.0	16.5								480.4%							
Operating Cash Flow	840.0	852.4	1,692.4	1,551.7	3,244.1	1,015.0	2,566.8	4,259.1	852.7								1.5%							
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								n.m.							
Payments for investments in intangible assets	-67.9	-52.0	-119.9	-89.2	-209.2	-66.3	-155.6	-275.5	-79.0								16.3%							
Payments from the disposal of intangible assets	20.6	4.8	25.4	10.1	35.4	2.3	12.4	37.7	4.4								-78.8%							
Payments for investments in property, plant and equipment	-430.5	-246.0	-676.5	-388.5	-1,065.0	-466.4	-854.9	-1,531.4	-572.3								32.9%							
Payments from the disposal of property, plant and equipment	17.1	-7.2	9.9	3.9	13.8	7.1	11.0	20.9	10.1								-40.7%							
Payments for acquisitions less acquired cash and cash equivalents (net)	-694.8	0.0	-694.8	-0.7	-695.5	-158.2	-159.0	-853.8	0.1								n.m.							
Payments from other divestments	3.7	0.5	4.2	0.1	4.3	-0.1	0.1	4.2	-0.1								n.m.							
Payments for investments in financial assets	-24.4	-23.2	-47.6	-168.7	-216.3	-148.1	-316.8	-364.4	-21.9								-10.3%							
Proceeds from the disposal of other financial assets	86.8	37.5	124.3	11.2	135.6	83.9	95.2	219.5	224.5								158.5%							
Payments for the acquisition of non-financial assets	-100.0	-500.0	-600.0	0.0	-600.0	0.0	-600.0	-897.0	0.0								797.0%							
Proceeds from the disposal of non-financial assets	100.0	0.0	100.0	0.0	100.0	500.0	500.0	600.0	100.0								0.0%							
Investing Cash Flow	-1,089.4	-785.7	-1,875.1	-621.9	-2,496.9	-245.8	-867.6	-2,742.7	-1,231.1								13.0%							
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								n.m.							
Dividend payments to Merck KGaA shareholders	0.0	-239.1	-239.1	0.0	-239.1	0.0	-239.1	-239.1	0.0								n.m.							
Dividend payments to non-controlling interests	-9.6	-1.6	-11.2	0.0	-11.2	-0.3	-0.3	-11.5	0.0								-100.0%							
Profit withdrawal by E.Merck KG	-90.5	-625.6	-716.1	0.0	-716.1	0.0	0.0	-716.1	-90.4								-0.2%							
Changes in financial liabilities to E.Merck KG	-406.0	976.7	570.7	-104.7	466.0	-442.7	-547.4	23.3	-0.8								-99.8%							
Other changes in net equity	0.3	-0.3	0.0	-0.1	-0.2	0.2	0.1	0.1	0.0								n.m.							
Changes in current and non-current financial liabilities	190.9	57.1	247.9	-804.4	-556.4	-55.3	-859.7	-611.7	215.6								13.0%							
Other changes from financing activities	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.0								-61.2%							
Financing Cash Flow	-315.0	167.2	-147.8	-809.1	-1,056.9	-498.1	-1,407.2	-1,555.0	124.5								n.m.							
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								n.m.							
Changes in cash and cash equivalents	-564.3	233.9	-330.5	20.8	-309.7	271.1	291.9	-38.6	-254.0								-55.0%							
Changes in cash and cash equivalents due to currency translation	3.5	7.3	10.8	4.1	14.9	-21.7	-17.7	-6.9	-15.7								n.m.							
Cash and cash equivalents as of January 1st	1,899.3	0.0	1,899.3	0.0	1,899.3	0.0	1,899.3	0.0	1,853.8								-2.4%							
Cash and cash equivalents	1,335.0	241.1	1,576.1	24.8	1,604.4	249.4	274.2	1,853.8	1,584.1								18.4%							
Changes in cash and cash equivalents due to change in scope of consolidation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								n.m.							

¹ As of January 1, 2023, the tranche of the Group Long-Term Incentive Plan to be paid out in the months following the balance sheet date is disclosed under other current non-financial liabilities and no longer under current provisions for employee benefits. For better comparability, the previous year's figures have been adjusted.

Due to rounding the sum of individual values may not add up to totals presented.

Balance Sheet Merck KGaA, Darmstadt, Germany
Group

€ million	2022				2023			
	31.Mrz	30.Jun	30.Sep	31. Dez	31.Mrz	30.Jun	30.Sep	31. Dez
Non-current assets	35,149.3	36,301.2	37,990.0	36,325.2	35,686.3			
Goodwill	17,760.8	18,573.4	19,534.1	18,414.7	18,077.4			
Other intangible assets	7,549.5	7,861.8	8,079.8	7,301.8	6,953.8			
Property, plant and equipment	7,302.9	7,573.4	7,945.6	8,203.0	8,217.9			
Investments accounted for using the equity method	2.8	3.0	3.1	2.9	2.9			
Other non-current receivables	24.5	25.7	28.1	27.1	23.9			
Other non-current financial assets	902.3	901.9	961.7	957.1	958.9			
Other non-current non-financial assets	104.8	99.5	104.1	99.1	99.6			
Non-current income tax receivables	9.8	9.7	9.4	9.8	9.3			
Deferred tax assets	1,492.0	1,252.9	1,324.0	1,309.6	1,342.5			

Current assets	11,085.3	12,415.9	12,943.1	12,200.9	12,950.7			
Inventories	4,142.8	4,473.7	4,859.9	4,632.1	4,889.6			
Trade and other current receivables	4,138.4	4,413.7	4,346.3	4,113.6	4,269.8			
Contract assets	207.0	156.1	137.2	128.4	132.6			
Other current financial assets	105.9	133.5	347.1	321.3	136.8			
Other current non-financial assets	792.8	1,362.5	1,335.0	705.4	1,515.8			
Current income tax receivables	359.9	297.0	313.2	446.3	421.9			
Cash and cash equivalents	1,338.5	1,579.6	1,604.4	1,853.8	1,584.1			
Assets held for sale	0.0	0.0	0.0	0.0	0.0			
Total assets	46,234.6	48,717.2	50,933.1	48,526.1	48,637.0			

Total equity	22,990.1	26,028.7	28,337.0	26,005.42	26,230.0			
Equity capital	565.2	565.2	565.2	565.21	565.2			
Capital reserves	3,813.7	3,813.7	3,813.7	3,813.73	3,813.7			
Retained earnings	16,450.0	18,014.6	18,825.1	18,462.87	19,250.0			
Gain/losses recognized in equity	2,090.5	3,561.4	5,056.3	3,085.59	2,520.3			
Non-controlling interest	70.7	73.7	76.7	77.99	80.7			

Non-current liabilities	13,037.5	12,970.7	13,184.4	13,007.2	12,850.8			
Non-current provisions for employee benefits	2,879.1	1,666.1	1,954.9	2,030.0	1,965.3			
Other non-current provisions	279.1	265.2	300.3	299.4	307.0			
Non-current financial debt	8,285.8	9,385.4	9,265.6	9,200.4	9,159.3			
Other non-current financial liabilities ¹	143.2	148.7	150.2	141.4	142.4			
Other non-current non-financial liabilities ¹	20.4	21.8	23.1	19.4	19.3			
Non-current income tax liabilities	40.7	41.3	40.9	38.1	38.0			
Deferred tax liabilities	1,389.2	1,442.1	1,449.4	1,278.5	1,219.4			

Current liabilities	10,206.9	9,717.8	9,411.8	9,513.5	9,556.2			
Current provisions for employee benefits ²	96.1	181.8	207.4	80.6	131.6			
Other current provisions	372.0	341.5	355.0	372.4	378.8			
Current financial debt	2,344.9	2,417.7	1,784.5	1,227.9	1,484.9			
Other current financial liabilities ¹	930.9	419.3	471.0	1,153.2	1,017.3			
Trade and other current payables	2,356.3	2,456.3	2,445.1	2,497.9	2,326.1			
Refund liabilities	873.2	972.1	968.1	912.3	947.1			
Current income tax liabilities	1,465.8	1,430.0	1,520.2	1,483.4	1,461.4			
Other current non-financial liabilities ^{1,2}	1,767.8	1,499.0	1,660.5	1,785.8	1,809.1			
Liabilities included in disposal groups classified as held for sale	0.0	0.0	0.0	0.0	0.0			

Total liabilities and stockholders' equity	46,234.6	48,717.2	50,933.1	48,526.1	48,637.0			
---	-----------------	-----------------	-----------------	-----------------	-----------------	--	--	--

Shares of Totals					Shares of Totals						
31.Mrz	30.Jun	30.Sep	31. Dez	31.Mrz	30.Jun	30.Sep	31. Dez	31.Mrz	30.Jun	30.Sep	31. Dez
76.0%	74.5%	74.6%	74.9%	73.4%	76.0%	74.5%	74.6%	74.9%	73.4%	76.0%	74.5%
38.4%	38.1%	38.4%	37.9%	37.2%	38.4%	38.1%	38.4%	37.9%	37.2%	38.4%	38.1%
16.3%	16.1%	15.9%	15.0%	14.3%	16.3%	16.1%	15.9%	15.0%	14.3%	16.3%	16.1%
15.8%	15.5%	15.6%	16.9%	16.9%	15.8%	15.5%	15.6%	16.9%	16.9%	15.8%	15.5%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%
2.0%	1.9%	1.9%	2.0%	2.0%	2.0%	1.9%	1.9%	2.0%	2.0%	2.0%	1.9%
0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
3.2%	2.6%	2.6%	2.7%	2.8%	3.2%	2.6%	2.6%	2.7%	2.8%	3.2%	2.6%

24.0%	25.5%	25.4%	25.1%	26.6%	24.0%	25.5%	25.4%	25.1%	26.6%	24.0%	25.5%
9.0%	9.2%	9.5%	9.5%	10.1%	9.0%	9.2%	9.5%	9.5%	10.1%	9.0%	9.2%
9.0%	9.1%	8.5%	8.5%	8.8%	9.0%	9.1%	8.5%	8.5%	8.8%	9.0%	9.1%
0.4%	0.3%	0.3%	0.3%	0.3%	0.4%	0.3%	0.3%	0.3%	0.3%	0.4%	0.3%
0.2%	0.3%	0.7%	0.7%	0.3%	0.2%	0.3%	0.7%	0.7%	0.3%	0.2%	0.3%
1.7%	2.8%	2.6%	1.5%	3.1%	1.7%	2.8%	2.6%	1.5%	3.1%	1.7%	2.8%
0.8%	0.6%	0.6%	0.9%	0.9%	0.8%	0.6%	0.6%	0.9%	0.9%	0.8%	0.6%
2.9%	3.2%	3.2%	3.8%	3.3%	2.9%	3.2%	3.2%	3.8%	3.3%	2.9%	3.2%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

49.7%	53.4%	55.6%	53.6%	53.9%	49.7%	53.4%	55.6%	53.6%	53.9%	49.7%	53.4%
1.2%	1.2%	1.1%	1.2%	1.2%	1.2%	1.2%	1.1%	1.2%	1.2%	1.2%	1.2%
8.2%	7.8%	7.5%	7.9%	7.8%	8.2%	7.8%	7.5%	7.9%	7.8%	8.2%	7.8%
35.6%	37.0%	37.0%	38.0%	39.6%	35.6%	37.0%	37.0%	38.0%	39.6%	35.6%	37.0%
4.5%	7.3%	9.9%	6.4%	5.2%	4.5%	7.3%	9.9%	6.4%	5.2%	4.5%	7.3%
0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%

28.2%	26.6%	25.9%	26.8%	26.4%	28.2%	26.6%	25.9%	26.8%	26.4%	28.2%	26.6%
6.2%	3.4%	3.8%	4.2%	4.0%	6.2%	3.4%	3.8%	4.2%	4.0%	6.2%	3.4%
0.6%	0.5%	0.6%	0.6%	0.6%	0.6%	0.5%	0.6%	0.6%	0.6%	0.6%	0.5%
17.9%	19.3%	18.2%	19.0%	18.8%	17.9%	19.3%	18.2%	19.0%	18.8%	17.9%	19.3%
0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
3.0%	3.0%	2.8%	2.6%	2.5%	3.0%	3.0%	2.8%	2.6%	2.5%	3.0%	3.0%

22.1%	19.9%	18.5%	19.6%	19.6%	22.1%	19.9%	18.5%	19.6%	19.6%	22.1%	19.9%
0.2%	0.4%	0.4%	0.2%	0.3%	0.2%	0.4%	0.4%	0.2%	0.3%	0.2%	0.4%
0.8%	0.7%	0.7%	0.8%	0.8%	0.8%	0.7%	0.7%	0.8%	0.8%	0.8%	0.7%
5.1%	5.0%	3.5%	2.5%	3.1%	5.1%	5.0%	3.5%	2.5%	3.1%	5.1%	5.0%
2.0%	0.9%	0.9%	2.4%	2.1%	2.0%	0.9%	0.9%	2.4%	2.1%	2.0%	0.9%
5.1%	5.0%	4.8%	5.1%	4.8%	5.1%	5.0%	4.8%	5.1%	4.8%	5.1%	5.0%
1.9%	2.0%	1.9%	1.9%	1.9%	1.9%	2.0%	1.9%	1.9%	1.9%	1.9%	2.0%
3.2%	2.9%	3.0%	3.1%	3.0%	3.2%	2.9%	3.0%	3.1%	3.0%	3.2%	2.9%
3.8%	3.1%	3.3%	3.7%	3.7%	3.8%	3.1%	3.3%	3.7%	3.7%	3.8%	3.1%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

	2022				2023			
	31.Mrz	30.Jun	30.Sep	31. Dez	31.Mrz	30.Jun	30.Sep	31. Dez
Financial debt	10,630.7	11,803.1	11,050.0	10,428.3	10,644.2			
Net financial debt	9,228.4	10,165.2	9,214.6	8,327.6	8,991.9			
Additions to Property, plant and equipment (excl. Leasing) ³	209.1	488.0	858.3	1,526.9	297.9			

Shares of Totals					Shares of Totals						
31.Mrz	30.Jun	30.Sep	31. Dez	31.Mrz	30.Jun	30.Sep	31. Dez	31.Mrz	30.Jun	30.Sep	31. Dez
23.0%	24.2%	21.7%	21.5%	21.9%	23.0%	24.2%	21.7%	21.5%	21.9%	23.0%	24.2%
20.0%	20.9%	18.1%	17.2%	18.5%	20.0%	20.9%	18.1%	17.2%	18.5%	20.0%	20.9%
n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.

Due to rounding the sum of individual values may not add up to totals presented

¹ As of January 1, 2023, wage- and salary-related liabilities is disclosed under other non-financial liabilities instead of under other financial liabilities as in the past.

For better comparability, the previous year's figures have been adjusted.

² As of January 1, 2023, the tranche of the Group Long-Term Incentive Plan to be paid out in the months following the balance sheet date are disclosed under other current non-financial liabilities and no longer under current provisions for employee benefits. For better comparability, the previous year's figures have been adjusted.

³ Figures are year-to-date figures from January 1st until stated end date.